DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
Precision Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Market Cap | $170.85M | $164.85M |
| Enterprise Value | $83.30M | $87.06M |
| PS Ratio | 3.79 | 3.60 |
| PB Ratio | 3.77 | 2.03 |
| P/TBV Ratio | 3.87 | 2.31 |
Enterprise value
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| EV / Sales | 1.85 | 2.43 |
Income (trailing twelve months)
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Revenue | $45.06M | $57.94M |
| Operating Income | -$36.40M | -$21.44M |
| Net Income | -$52.73M | -$22.46M |
| EBITDA | -$35.15M | -$16.91M |
Margins
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Operating Margin | -80.8% | -44.5% |
| Profit Margin | -117.0% | -39.2% |
| EBITDA Margin | -78.0% | -31.3% |
| FCF Margin | -115.3% | -8.85% |
Returns
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -132.9% | -53.1% |
| Return on Assets (ROA) | -44.9% | -41.0% |
| Return on Capital Employed (ROCE) | -30.6% | -37.8% |
Growth
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3473.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 10.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 7.13% | 6.42% |
Balance sheet
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $87.55M | $62.42M |
| Net Cash (Debt) | $87.55M | $15.68M |
| Net Cash Per Share | $3.17 | $0.66 |
| Equity (Book Value) | $45.29M | $48.79M |
| Book Value Per Share | $1.64 | $1.36 |
| Tangible Book Value | $44.20M | $23.06M |
| Working Capital | $84.41M | $75.77M |
Financial position
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Current Ratio | 12.82 | 3.30 |
| Quick Ratio | 12.26 | 2.39 |
| Interest Coverage | -27.55 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$51.90M | -$12.35M |
| Capital Expenditures | -$37.00K | -$1.06M |
| Free Cash Flow | -$51.94M | -$20.28M |
| FCF Per Share | -$1.88 | -$0.42 |
Efficiency
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.38 | 0.38 |
| Revenue Per Employee | $662.57K | $398.96K |
| Profits Per Employee | -$775.47K | -$703.34K |
| Employee Count | 68 | 74 |
Dividends and yields
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -30.9% | -22.7% |
| FCF Yield | -30.4% | -9.07% |
Shares
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 27,601,600 | 58,179,650 |
| Shares Change (YoY) | 130.1% | 11.1% |
| Shares Change (QoQ) | 2.43% | 0.54% |
| Float | 26,780,600 | 49,173,100 |
| Shares Held by Insiders | 2.97% | 11.6% |
| Shares Held by Institutions | 64.0% | 59.4% |
Scores
| Measure | Precision Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -4.96 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Precision Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.